Israeli and Portuguese scientists unveiled a novel COVID-19 vaccine that is not only effective against all major variants but can be administered as a nasal spray and — unlike conventional vaccines — stored at room temperature. Moreover, the nano-technology behind it could be adapted for other infectious diseases and other personalized treatments.

The innovative vaccine is the brainchild of a collaboration between Prof. Ronit Satchi-Fainaro’s lab at Tel Aviv University and Prof. Helena Florindo’s team at the University of Lisbon. Published in the peer-reviewed Advanced Science journal, the scientists utilized synthesized nanoparticles to effectively target the virus without relying on traditional mRNA technology.

The nano-vaccine leverages a unique 200-nanometer particle to train the immune system to combat COVID-19 variants, from Beta to Omicron, with effectiveness comparable to existing vaccines. Instead of the mRNA-based approach used by the Moderna and Pfize pharmaceutical companies, the researchers identified two key amino acid sequences in the virus’s protein, synthesized them, and encapsulated them in nanoparticles.

“Our approach was inspired by a decade of work on cancer vaccines. When COVID-19 emerged, we adapted our platform to develop a vaccine that is not only effective but also highly accessible,” said Satchi-Fainaro.

The nano-vaccine offers two major advantages over existing options.

First, as a nasal spray, it can be self-administered, eliminating the need for needles or trained healthcare personnel.

Second, its storage and transportation requirements are minimal. Pfizer and Moderna vaccines require ultra-cold storage because of the inherent instability of mRNA, the molecule at the heart of these vaccines. mRNA is a single-stranded nucleic acid that is highly fragile and susceptible to degradation by environmental factors.

In contrast, the nano-vaccine can be stored as a powder at room temperature. For use, the powder is mixed with saline to create the spray.

This feature was tested through the European Union’s ISIDORe feasibility program, where the vaccine powder was shipped at room temperature to France for testing. The results demonstrated efficacy on par with Pfizer’s vaccine.

The nano-vaccine platform has potential beyond COVID-19. It could be adapted for other infectious diseases, personalized cancer treatments, and chronic conditions like autoimmune disorders, the researcher explained.

“Our technology is not just a solution for COVID-19; it is a platform for future vaccines,” said Prof. Satchi-Fainaro. “This plug-and-play method allows rapid adaptation to target other infectious diseases or even cancer.”

PHOTO: Use according to Section 27 A